Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-03-03 Sale | 2026-03-05 6:55 pm | AN2 Therapeutics Inc. | ANTX | Williams Sarah Joanne Principal Accounting Officer | 327 | $1.06 | $347 | 66,848 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 8:15 pm | AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer | 8,807 | $1.0086 | $8,883 | 75,363 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 8:15 pm | AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer | 6,462 | $1.007 | $6,507 | 59,086 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 8:13 pm | AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer | 9,251 | $1.0088 | $9,332 | 75,823 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 8:12 pm | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks | 24,854 | $1.0044 | $24,962 | 152,499 (Direct) | View |
| 2025-11-04 Sale | 2025-11-06 6:12 pm | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks | 2,819 | $1.14 | $3,214 | 177,353 (Direct) | View |
| 2025-11-04 Sale | 2025-11-06 6:11 pm | AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer | 765 | $1.14 | $872 | 65,548 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-03-19 Option Award | 2026-03-23 7:16 pm | N/A 2031-04-29 | AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer | 221,965 | $0 | 221,965 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:16 pm | N/A 2032-05-11 | AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer | 165,615 | $0 | 165,615 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:13 pm | N/A 2031-04-29 | AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director | 44,769 | $0 | 44,769 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:11 pm | N/A 2032-05-11 | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director | 44,466 | $0 | 44,466 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:10 pm | N/A 2031-04-29 | AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director | 59,103 | $0 | 59,103 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:09 pm | N/A 2032-05-04 | AN2 Therapeutics Inc. | ANTX | FitzPatrick Margaret M Director | 45,567 | $0 | 45,567 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:08 pm | N/A 2031-04-29 | AN2 Therapeutics Inc. | ANTX | Wong Stephanie Director | 59,103 | $0 | 59,103 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:07 pm | N/A 2031-04-29 | AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director | 134,103 | $0 | 134,103 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:06 pm | N/A 2032-10-13 | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks | 142,150 | $0 | 142,150 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:04 pm | N/A 2032-02-17 | AN2 Therapeutics Inc. | ANTX | Spigelman Melvin K Director | 51,045 | $0 | 51,045 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:02 pm | N/A 2032-05-11 | AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director | 44,466 | $0 | 44,466 (Direct) | View |
| 2026-03-19 Option Award | 2026-03-23 7:00 pm | N/A 2031-04-29 | AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer | 742,649 | $0 | 742,649 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:41 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks | 150,000 | $0 | 307,499 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:40 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer | 115,000 | $0 | 195,363 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:39 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Williams Sarah Joanne Principal Accounting Officer | 48,375 | $0 | 67,175 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:36 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer | 336,750 | $0 | 1,853,012 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:35 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer | 115,000 | $0 | 195,823 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:29 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director | 20,400 | $0 | 20,400 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:29 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director | 20,400 | $0 | 20,400 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:28 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Wong Stephanie Director | 20,400 | $0 | 20,400 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:24 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director | 20,400 | $0 | 20,400 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:21 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Spigelman Melvin K Director | 20,400 | $0 | 20,400 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:21 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director | 20,400 | $0 | 20,400 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:17 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | FitzPatrick Margaret M Director | 20,400 | $0 | 20,400 (Direct) | View |
| 2026-02-20 Option Award | 2026-02-23 4:11 pm | N/A 2036-02-19 | AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director | 20,400 | $0 | 20,400 (Direct) | View |
Ownership | 2026-02-03 6:08 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Williams Sarah Joanne Principal Accounting Officer | 0 | $0 | 64,375 (Direct) | View |
| 2026-01-12 Option Award | 2026-01-14 5:07 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director | 11,560 | $0 | 2,425,979 (Direct) | View |
| 2026-01-12 Option Award | 2026-01-14 5:06 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director | 3,650 | $0 | 16,905 (Direct) | View |
| 2026-01-12 Option Award | 2026-01-14 5:06 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director | 11,560 | $0 | 75,309 (Direct) | View |
| 2025-10-10 Option Award | 2025-10-14 4:01 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director | 10,367 | $0 | 63,749 (Direct) | View |
| 2025-10-10 Option Award | 2025-10-14 4:01 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director | 10,367 | $0 | 2,414,419 (Direct) | View |
| 2025-10-10 Option Award | 2025-10-14 4:01 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director | 3,274 | $0 | 13,255 (Direct) | View |
| 2025-07-10 Option Award | 2025-07-11 6:23 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director | 11,875 | $0 | 2,404,052 (Direct) | View |